Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Clinical Biomarkers Market - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, End User, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
This data offers insights into market dynamics from 2023 through 2033, revealing patterns in various sectors and projecting the direction in which the industry is headed.
Clinical biomarkers play an indispensable role in the early diagnosis and management of diseases, with implications across predictive, prognostic, and diagnostic applications. The current research report underscores the exponential increase in the value of the global clinical biomarkers market, initially pegged at $24.80 billion in 2023, with forecasts up to $53.20 billion by 2033, expanding at a compelling compound annual growth rate (CAGR) of 7.93% over the forecast period.
Highlighted within the report are the pivotal offerings and technologies that are shaping the market, among which Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Immunohistochemistry (IHC) are key contributors to the projected growth. The report further dissects market segments to pinpoint areas that are experiencing exceptional growth, such as cancer biomarkers and services delivered by contract research organizations (CROs).
Market Dynamics and Industrial Impact
- The heightened need for advanced biomarker-based assays in industries such as oncology, cardiology, and neurology is driving significant investments by biopharmaceutical entities.
- Technological advancements including NGS and PCR are integral in leading the way towards more efficient diagnostic and therapeutic processes.
- An increased focus on personalized healthcare and precision medicine is encouraging the utilization of biomarkers in clinical settings.
Geographic Spotlight and Segmental Analysis
- The report also offers a geographic analysis, laying emphasis on regions like North America and Asia-Pacific, where technology adoption and healthcare advancements are surging.
- By offering insights into market segmentation by end-user, the report highlights the pivotal role of CROs in accelerating market advancement.
Anticipated Developments and Innovations
The report provides crucial details of recent industry developments, including the launch of new diagnostics tests, strategic collaborations, and FDA approvals. These developments signify the market's commitment to innovation and its alignment with the overarching goal of improving patient outcomes.
Challenges Faced by the Market
Despite the industry's growth, challenges persist, particularly in low-income regions where the adoption of advanced clinical biomarker products/services is hindered by the high costs associated with technology and infrastructure development. The report delves into these issues, offering an in-depth analysis of market constraints.
Strategy and Competitive Landscape
The report encompasses growth strategies, product innovations, and a competitive strategy analysis. Market players and key stakeholders can gain strategic insights from the research, enabling them to make informed decisions that cater to evolving industry demands.
The analyzed data highlights the role of biomarkers in contemporary clinical diagnostics and their growing importance in disease examination and drug development. Leveraging such comprehensive market studies aids businesses, healthcare practitioners, and researchers in navigating the complexities of the clinical biomarkers landscape with greater clarity and strategic acuity.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 255 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value (USD) in 2023 | $24.8 Billion |
| Forecasted Market Value (USD) by 2033 | $53.2 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
Companies Profiled
- Abbott Laboratories
- Agilent Technologies, Inc.
- ALCEN
- Arsenal Capital Partners
- Azenta Life Sciences
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- bioMérieux S.A.
- BGI
- Broad Institute
- Charles River Laboratories
- Caris Life Sciences
- CENTOGENE N.V.
- Discovery Life Sciences (DLS)
- Enzo Biochem Inc.
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- Novogene Co., Ltd.
- Personalis Inc.
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Q2 Solutions
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/d8bv8l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
